İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - estradiolum inn - forðaplástur - 25 míkróg

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - estradiolum inn - forðaplástur - 37,5 míkróg

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - estradiolum inn - forðaplástur - 50 míkróg

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - estradiolum inn - forðaplástur - 75 míkróg

Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cystic fibrosis - Önnur öndunarfæri - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

novo nordisk a/s* - estradiol; norethisteronum acetat - filmuhúðuð tafla

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

besins healthcare ireland limited - estradiol - hlaup - 0,6 mg/g

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris aps - estradiol - tafla - 1 mg

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris aps - estradiol - tafla - 2 mg

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris aps - norethisteronum acetat; estradiol - tafla - 2 mg+1 mg